Late Phase II Clinical Study of Vinorelbine Monotherapy in Advanced or Recurrent Breast Cancer Previously Treated with Anthracyclines and

Background:Atpresent, it is oneof themost important issues for the treatmentofbreast cancer to develop thestandard therapy forpatientspreviously treatedwithanthracyclinesand taxanes.With the objective of determining the usefulness of vinorelbinemonotherapy in patients with advanced or recurrent breast cancer after standard therapy, we evaluated the efficacy and safety of vinorel-bine in patients previously treated with anthracyclines and taxanes. Methods:Vinorelbine was administered at a dose level of 25mg/m2 intravenously on days 1 and 8 of a 3week cycle. Patients were given three ormore cycles in the absence of tumor progression. A maximum of nine cycles were administered